A Phase Ib/II Study of Trovocabtagene Autoleucel (C-CAR088), an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

被引：0

作者：

An, Gang ^{[1
]}

Xu, Yan ^{[1
]}

Yi, Shuhua ^{[1
]}

Lyu, Rui ^{[1
]}

Huang, Jiaqi ^{[2
]}

Li, Wensi ^{[2
]}

Zhang, Yiran ^{[2
]}

Lan, Liping ^{[2
]}

Qiu, Lugui ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol,Haihe Lab Cell Ecosyst, Tianjin, Peoples R China

[2] Shanghai AbelZeta Ltd, Shanghai, Peoples R China

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-194774

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：7235 / 7236

页数：2

共 50 条

[21] CT053, Anti-BCMA CAR T-cell therapy for Relapsed/Refractory Multiple Myeloma: Proof of Concept results from a Phase I Study
Hao, Siguo
Jin, Jie
Yu, Kang
Li, Zonghai
Zhang, Wenhao
Yang, Min
Jiang, Songfu
Chen, Peishuai
Ma, Liyuan
Meng, Haitao
He, Mingxia
Wang, Wei
Chen, Linjun
Huang, Xin
Xing, Chongyun
Yuan, Daijing
Tao, Rong
Wang, Shasha
Dai, Lihui
Ma, Hong
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E54 - E55
[22] Hematopoietic reconstitution and infections after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma are associated with pre-CAR-T bridging therapies
Frenking, Jan
Kauer, Joseph
Hajiyianni, Marina
Mai, Elias
Michel, Christian
Sester, Lilli
John, Lukas
Mueller-Tidow, Carsten
Goldschmidt, Hartmut
Weinhold, Niels
Schmitt, Anita
Schmitt, Michael
Dreger, Peter
Sauer, Sandra
Raab, Marc
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S38 - S39
[23] An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
Wang, Qingming
Wei, Runhong
Guo, Shufang
Min, Chao
Zhong, Xiong
Huang, Hui
Cheng, Zhi
CANCER GENE THERAPY, 2024, 31 (01) : 108 - 118
[24] An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
Qingming Wang
Runhong Wei
Shufang Guo
Chao Min
Xiong Zhong
Hui Huang
Zhi Cheng
Cancer Gene Therapy, 2024, 31 : 420 - 426
[25] Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
D'Agostino, Mattia
Raje, Noopur
LEUKEMIA, 2020, 34 (01) : 21 - 34
[26] Increased Bone Turnover and Decreased BCMA Levels in Patients with Response to Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma
Ussmann, Jule
Fischer, Luise
Born, Patrick
Grieb, Nora
Hoffmann, Sandra
Baber, Ronny
Wang, Song-Yau
Kloetzer, Christina
Heyn, Simone
Herling, Marco
Herling, Carmen
Jentzsch, Madlen
Franke, Georg-Nikolaus
Hofbauer, Lorenz
Platzbecker, Uwe
Vucinic, Vladan
Weidner, Heike
Merz, Maximilian
BLOOD, 2023, 142
[27] A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.
Cornell, Robert F.
Locke, Frederick Lundry
Bishop, Michael Russell
Orlowski, Robert Z.
Larson, Sarah Marie
Borrello, Ivan
Giralt, Sergio
Kumar, Shaji
Nooka, Ajay K.
Raje, Noopur S.
Rossi, John M.
Thomrongsith, Lisa
Xue, Allen
Roberts, Zachary
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[28] Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
Mattia D’Agostino
Noopur Raje
Leukemia, 2020, 34 : 21 - 34
[29] Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease
Deng, Haobin
Liu, Meijing
Yuan, Ting
Zhang, Huan
Cui, Rui
Li, Jingyi
Yuan, Jijun
Wang, Xiaofang
Wang, Yafei
Deng, Qi
FRONTIERS IN IMMUNOLOGY, 2021, 12
[30] Anti-BCMA CAR T-Cell Therapy in Patients with Refractory Myasthenia Gravis
Qin, Chuan
Tian, Dai-Shi
Dong, Ming-Hao
Hing, Michael
Zhou, Luo-Qi
Wang, Wen
Song-Bai
Li, Chun-Rui
Wang, Di
Zhang, Min
Bu, Bi-Tao
zu Hoerste, Gerd Meyer
Wang, Wei
ANNALS OF NEUROLOGY, 2024, 96 : S98 - S99

← 1 2 3 4 5 →